ASLAN Pharmaceuticals Limited (ASLN)

ASLAN Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	18.4	21.25	56.9	90.17	14.32	22.2
Short-Term Investments	0	0	0	0	0.14	0
Cash & Cash Equivalents	18.4	21.25	56.9	90.17	14.46	22.2
Cash Growth	-68.00%	-62.65%	-36.89%	523.47%	-34.86%	-23.20%
Other Current Assets	2.18	2.88	3.98	3.61	1.04	0.07
Total Current Assets	20.58	24.13	60.88	93.78	15.5	22.27
Property, Plant & Equipment	0.18	0.26	0.29	0.23	0.48	0.77
Long-Term Investments	0.24	0.24	0.01	0.49	0	0.2
Goodwill and Intangibles	0	0	0.01	0.01	0	0
Other Long-Term Assets	0	0	0	0	0.1	0.11
Total Long-Term Assets	0.41	0.5	0.31	0.74	0.58	1.08
Total Assets	20.99	24.63	61.19	94.52	16.08	23.35
Accounts Payable	12.01	11	15.11	5.93	6.6	5.12
Current Debt	7.32	2.03	8.05	0.42	4.06	0.26
Other Current Liabilities	0.28	0.09	0	0	0	0
Total Current Liabilities	19.6	13.11	23.16	6.36	10.66	5.38
Long-Term Debt	19.35	24.8	29.66	30.86	15.46	18.38
Other Long-Term Liabilities	0	0	0	0	0.11	0.18
Total Long-Term Liabilities	19.35	24.8	29.66	30.86	15.58	18.57
Total Liabilities	38.95	37.91	52.82	37.21	26.23	23.95
Total Debt	26.67	26.83	37.71	31.28	19.52	18.65
Debt Growth	-29.71%	-28.87%	20.56%	60.23%	4.68%	33.45%
Retained Earnings	-330.99	-321.07	-278.39	-227	-195.68	-179.48
Shareholders' Equity	-17.96	-13.29	8.37	57.3	-10.45	-1.68
Net Cash / Debt	-8.27	-5.57	19.19	58.89	-5.06	3.55
Net Cash / Debt Growth	-	-	-67.41%	-	-	-76.20%
Net Cash Per Share	-	-0.01	0.06	0.18	-0.03	0.02
Working Capital	0.97	11.02	37.71	87.42	4.84	16.89
Book Value Per Share	-7.70	-6.46	4.80	35.19	-10.88	-2.07

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).